{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:45:09Z","timestamp":1791945909559,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Medical Science Research Project of Hebei Provincial Healthcare Commission","award":["20241174"],"award-info":[{"award-number":["20241174"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genes Genom"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13258-026-01791-7","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T09:09:49Z","timestamp":1785229789000},"page":"1295-1309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inhibition of PI3K\/AKT\/mTOR pathway suppresses growth of oral squamous cell carcinoma in 2D and 3D in vitro model and animal model"],"prefix":"10.1007","volume":"48","author":[{"given":"Hui","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"6","key":"1791_CR1","first-page":"741","volume":"28","author":"F Adeola","year":"2018","unstructured":"Adeola F (2018) Normalization of gene expression by quantitative RT-PCR in human cell line: comparison of 12 endogenous reference genes. Ethiop J Health Sci 28(6):741\u2013748","journal-title":"Ethiop J Health Sci"},{"issue":"1","key":"1791_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/hed.24560","volume":"39","author":"A Bozec","year":"2017","unstructured":"Bozec A, Ebran N, Radosevic-Robin N, Chamorey E, Yahia HB, Marcie S, Gautier M, Penault-Llorca F, Milano G (2017) Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer. Head Neck 39(1):151\u2013159","journal-title":"Head Neck"},{"key":"1791_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105451","volume":"121","author":"A Chamoli","year":"2021","unstructured":"Chamoli A, Gosavi AS, Shirwadkar UP, Wangdale KV, Behera SK, Kurrey NK, Kalia K, Mandoli A (2021) Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics. Oral Oncol 121:105451","journal-title":"Oral Oncol"},{"issue":"4","key":"1791_CR4","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.3390\/ijms24044096","volume":"24","author":"RT Chitturi Suryaprakash","year":"2023","unstructured":"Chitturi Suryaprakash RT, Shearston K, Farah CS, Fox SA, Iqbal MM, Kadolsky U, Zhong X, Saxena A, Kujan O (2023) A novel preclinical in vitro 3D model of oral carcinogenesis for biomarker discovery and drug testing. Int J Mol Sci 24(4):4096","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1791_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043418","volume":"7","author":"YJ Choi","year":"2012","unstructured":"Choi YJ, Park YJ, Park JY, Jeong HO, Kim DH, Ha YM, Kim JM, Song YM, Heo HS, Yu BP, Chun P, Moon HR, Chung HY (2012) Inhibitory effect of mTOR activator MHY1485 on autophagy: suppression of lysosomal fusion. PLoS ONE 7(8):e43418","journal-title":"PLoS ONE"},{"issue":"16","key":"1791_CR6","doi-asserted-by":"publisher","first-page":"15293","DOI":"10.1007\/s00432-023-05277-x","volume":"149","author":"Z Davoodi-Moghaddam","year":"2023","unstructured":"Davoodi-Moghaddam Z, Jafari-Raddani F, Delshad M, Pourbagheri-Sigaroodi A, Bashash D (2023) Inhibitors of the PI3K\/AKT\/mTOR pathway in human malignancies; trend of current clinical trials. J Cancer Res Clin Oncol 149(16):15293\u201315310","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"1791_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.tcb.2015.06.002","volume":"25","author":"CC Dibble","year":"2015","unstructured":"Dibble CC, Cantley LC (2015) Regulation of mTORC1 by PI3K signaling. Trends Cell Biol 25(9):545\u2013555","journal-title":"Trends Cell Biol"},{"issue":"6","key":"1791_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100880","volume":"9","author":"M Dumble","year":"2014","unstructured":"Dumble M, Crouthamel MC, Zhang SY, Schaber M, Levy D, Robell K, Liu Q, Figueroa DJ, Minthorn EA, Seefeld MA, Rouse MB, Rabindran SK, Heerding DA, Kumar R (2014) Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS ONE 9(6):e100880","journal-title":"PLoS ONE"},{"issue":"1","key":"1791_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1042\/BJ20061489","volume":"404","author":"SI Gharbi","year":"2007","unstructured":"Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, Waterfield MD (2007) Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 404(1):15\u201321","journal-title":"Biochem J"},{"issue":"1","key":"1791_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B et al (2023) PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer 22(1):138","journal-title":"Mol Cancer"},{"issue":"9","key":"1791_CR11","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.3390\/ijms21093285","volume":"21","author":"C Harsha","year":"2020","unstructured":"Harsha C, Banik K, Ang HL, Girisa S, Vikkurthi R, Parama D, Rana V, Shabnam B, Khatoon E, Kumar AP, Kunnumakkara AB (2020) Targeting AKT\/mTOR in oral cancer: mechanisms and advances in clinical trials. Int J Mol Sci 21(9):3285. https:\/\/doi.org\/10.3390\/ijms21093285","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1791_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj G, Manning BD (2020) The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer 20(2):74\u201388","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1791_CR13","doi-asserted-by":"publisher","first-page":"2355703","DOI":"10.1080\/15384047.2024.2355703","volume":"25","author":"C Huo","year":"2024","unstructured":"Huo C, Wu D, Li X, Zhang Y, Hu B, Zhang T, Ren J, Wang T, Liu Y (2024) eIf3a mediates malignant biological behaviors in colorectal cancer through the PI3K\/AKT signaling pathway. Cancer Biol Ther 25(1):2355703","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"1791_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR (2020) Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6(1):92","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1791_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41391-020-00299-9","volume":"24","author":"MK Labriola","year":"2021","unstructured":"Labriola MK, Atiq S, Hirshman N, Bitting RL (2021) Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies. Prostate Cancer Prostatic Dis 24(2):301\u2013309. https:\/\/doi.org\/10.1038\/s41391-020-00299-9","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"1791_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.31267","volume":"239","author":"N Li","year":"2024","unstructured":"Li N, Wang XL, Ge R, Wang Y, Tian XL, Zhu GQ, Zhou B (2024) FNDC5 inhibits malignant growth of human cervical cancer cells via restraining PI3K\/AKT pathway. J Cell Physiol 239(6):e31267","journal-title":"J Cell Physiol"},{"issue":"1","key":"1791_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-019-0841-3","volume":"13","author":"Y Liu","year":"2020","unstructured":"Liu Y, Lu LL, Wen D, Liu DL, Dong LL, Gao DM, Bian XY, Zhou J, Fan J, Wu WZ (2020) MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming. J Hematol Oncol 13(1):12","journal-title":"J Hematol Oncol"},{"issue":"12","key":"1791_CR18","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1177\/10600280241241531","volume":"58","author":"AJ Luboff","year":"2024","unstructured":"Luboff AJ, DeRemer DL (2024) Capivasertib: a novel AKT inhibitor approved for hormone-receptor-positive, HER-2-negative metastatic breast cancer. Ann Pharmacother 58(12):1229\u20131237","journal-title":"Ann Pharmacother"},{"issue":"10","key":"1791_CR19","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.3390\/cancers15102793","volume":"15","author":"S Miyamoto","year":"2023","unstructured":"Miyamoto S, Nishikiori N, Sato T, Watanabe M, Umetsu A, Tsugeno Y, Hikage F, Sasaya T, Kato H, Ogi K, Furuhashi M, Ohguro H, Miyazaki A (2023) Three-dimensional spheroid configurations and cellular metabolic properties of oral squamous carcinomas are possible pharmacological and pathological indicators. Cancers (Basel) 15(10):2793","journal-title":"Cancers (Basel)"},{"key":"1791_CR20","doi-asserted-by":"crossref","unstructured":"Rathi E, Udupa KS, Prasada K S, Pai KSR, Kini SG (2025) Design of PI3K-mTOR dual inhibitors for ovarian cancer: are we on the right track? Curr Med Chem 32(6):1121\u20131143 (.","DOI":"10.2174\/0109298673293028240326051835"},{"key":"1791_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.gene.2019.02.076","volume":"698","author":"S Noorolyai","year":"2019","unstructured":"Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B (2019) The relation between PI3K\/AKT signalling pathway and cancer. Gene 698:120\u2013128","journal-title":"Gene"},{"issue":"6","key":"1791_CR22","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.3892\/or.2014.3134","volume":"31","author":"G Ren","year":"2014","unstructured":"Ren G, Hu J, Wang R, Han W, Zhao M, Zhou G, Zhang C, Zhang Z (2014) Rapamycin inhibits Toll-like receptor 4-induced pro-oncogenic function in head and neck squamous cell carcinoma. Oncol Rep 31(6):2804\u20132810","journal-title":"Oncol Rep"},{"issue":"14","key":"1791_CR23","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1002\/cncr.32929","volume":"126","author":"TY Seiwert","year":"2020","unstructured":"Seiwert TY, Kochanny S, Wood K, Worden FP, Adkins D, Wade JL, Sleckman BG, Anderson D, Brisson RJ, Karrison T et al (2020) A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent\/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Cancer 126(14):3237\u20133243","journal-title":"Cancer"},{"key":"1791_CR24","doi-asserted-by":"crossref","unstructured":"Serter Kocoglu S, Sunay FB, Akkaya PN (2023) Effects of monensin and rapamycin combination therapy on tumor growth and apoptosis in a xenograft mouse model of neuroblastoma. Antibiotics (Basel) 12(6)","DOI":"10.3390\/antibiotics12060995"},{"key":"1791_CR25","doi-asserted-by":"crossref","unstructured":"Shukla P, Yeleswarapu S, Heinrich MA, Prakash J, Pati F (2022) Mimicking tumor microenvironment by 3D bioprinting: 3D cancer modeling. Biofabrication 14(3)","DOI":"10.1088\/1758-5090\/ac6d11"},{"issue":"4","key":"1791_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.oraloncology.2014.11.012","volume":"51","author":"DR Simpson","year":"2015","unstructured":"Simpson DR, Mell LK, Cohen EE (2015) Targeting the PI3K\/AKT\/mTOR pathway in squamous cell carcinoma of the head and neck. Oral Oncol 51(4):291\u2013298","journal-title":"Oral Oncol"},{"key":"1791_CR27","doi-asserted-by":"crossref","unstructured":"Takahashi N, Cho P, Selfors LM, Kuiken HJ, Kaul R, Fujiwara T, Harris IS, Zhang T, Gygi SP, Brugge JS (2020) 3D culture models with CRISPR screens reveal hyperactive NRF2 as a prerequisite for spheroid formation via regulation of proliferation and ferroptosis. Mol Cell 80(5):828\u2013844 e826","DOI":"10.1016\/j.molcel.2020.10.010"},{"issue":"7","key":"1791_CR28","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1158\/0008-5472.CAN-18-1220","volume":"79","author":"Z Wang","year":"2019","unstructured":"Wang Z, Feng X, Molinolo AA, Martin D, Vitale-Cross L, Nohata N, Ando M, Wahba A, Amornphimoltham P, Wu X et al (2019) 4E-BP1 Is a tumor suppressor protein reactivated by mTOR inhibition in head and neck cancer. Cancer Res 79(7):1438\u20131450","journal-title":"Cancer Res"},{"issue":"1","key":"1791_CR29","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1186\/s12967-023-04703-5","volume":"21","author":"S Wang","year":"2023","unstructured":"Wang S, Cheng Z, Cui Y, Xu S, Luan Q, Jing S, Du B, Li X, Li Y (2023) PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K\/AKT\/mTOR signaling pathway. J Transl Med 21(1):819","journal-title":"J Transl Med"},{"issue":"991","key":"1791_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177309","volume":"15","author":"K Wawrzak-Pienkowska","year":"2025","unstructured":"Wawrzak-Pienkowska K, Pienkowski T, Tankiewicz-Kwedlo A, Ciborowski M, Kurek K, Pawlak D (2025) Differences in treatment outcome between translational platforms in developing therapies for gastrointestinal cancers. Eur J Pharmacol 15(991):177309","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"1791_CR31","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1177\/00220345241240997","volume":"103","author":"J Zhou","year":"2024","unstructured":"Zhou J, Liu C, Amornphimoltham P, Cheong SC, Gutkind JS, Chen Q, Wang Z (2024) Mouse models for head and neck squamous cell carcinoma. J Dent Res 103(6):585\u2013595","journal-title":"J Dent Res"}],"container-title":["Genes & Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13258-026-01791-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13258-026-01791-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13258-026-01791-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:03:34Z","timestamp":1791943414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13258-026-01791-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1791"],"URL":"https:\/\/doi.org\/10.1007\/s13258-026-01791-7","relation":{},"ISSN":["1976-9571","2092-9293"],"issn-type":[{"value":"1976-9571","type":"print"},{"value":"2092-9293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All in vivo experiments were performed following the guidelines of the Institutional Review Board of The Fourth Hospital of Hebei Medical University (IACUC Issue No. 20240730).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Author confirms: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all co-authors, if any.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}